JP Morgan Chase
ANAB icon

JP Morgan Chase’s AnaptysBio ANAB Stock Holding History

JP Morgan Chase’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-800
Closed -$13K – 5267
2019
Q4 		$13K Buy
800
+100
+14% +$2.37K ﹤0.01% 5365
2019
Q3 		$24K Sell
700
-4,300
-86% -$205K ﹤0.01% 5361
2019
Q2 		$273K Sell
5,000
-30,000
-86% -$2.16M ﹤0.01% 4526
2019
Q1 		$2.56M Buy
+35,000
New +$2.42M ﹤0.01% 3166

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase's ANAB Position: Q1 2026 in Review

JP Morgan Chase increased its AnaptysBio (ANAB) stake by 6.7% in Q1 2026, buying an estimated $39.2K and bringing the position to 11,645 shares worth $645K. The position accounts for ﹤0.01% of the portfolio, ranked #4850.

JP Morgan Chase first reported a position in ANAB in Q1 2017 and has held it in 37 quarters since. The position peaked at $9.02M in Q2 2018. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • JP Morgan Chase held 11,645 shares of AnaptysBio worth $645K as of Q1 2026.
  • JP Morgan Chase bought 729 AnaptysBio shares in Q1 2026, an estimated $39.2K.
  • AnaptysBio made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4850 holding.
  • JP Morgan Chase first reported a position in AnaptysBio in Q1 2017 and has held it in 37 quarters since.
  • JP Morgan Chase's AnaptysBio position peaked at $9.02M in Q2 2018.
  • 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.